Search
Displaying all 2 results
Alirocumab Action Pathway (New)
smpdb.ca/view/SMP0125308Drug actionTherefore by inhibiting PCSK9's actions, alirocumab allows for more LDL-C reuptake by the liver and facilitates a higher rate of clearance. … Alirocumab is a PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of
Enzymes: AlirocumabEvolocumab Action Pathway
smpdb.ca/view/SMP0125309Drug actionTherefore by inhibiting PCSK9's actions, alirocumab allows for more LDL-C reuptake by the liver and facilitates a higher rate of clearance.